CYBN Key Statistics, Chart & Performance
The current stock price of CYBN is 8.28 USD. In the past month the price increased by 47.07%. In the past year, price decreased by -18.02%.
CYBN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CYBN. When comparing the yearly performance of all stocks, CYBN turns out to be only a medium performer in the overall market: it outperformed 58.99% of all stocks.
CYBN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYBN Forecast & Estimates
CYBN Ownership
About CYBN
Company Profile
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Company Info
CYBIN INC
100 King Street West, Suite 5600
TORONTO ONTARIO CA
CEO: Doug Drysdale
Employees: 50
Phone: 19087648385
CYBIN INC / CYBN FAQ
Can you describe the business of CYBIN INC?
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
What is the current price of CYBN stock?
The current stock price of CYBN is 8.28 USD. The price increased by 1.22% in the last trading session.
What is the dividend status of CYBIN INC?
CYBN does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYBN stock?
CYBN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Should I buy CYBN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CYBN.